T H 17 cells promote pathology in a variety of autoimmune conditions, and therapies targeting T H 17 cells are proving highly effective in certain autoimmune diseases 1, 2 . IL-17, the prototypical T H 17 cytokine, targets non-hematopoietic cells to induce the production of chemokines that attract myeloid cells, pro-inflammatory cytokines such as IL-6 and antimicrobial peptides 2 . T H 17 cells are therefore important regulators of extracellular bacterial and fungal pathogens. In the healthy skin and gut, IL-17 maintains microbial homeostasis without overt inflammation and supports gut epithelial healing following toxic injury 3, 4 . IL-17 also promotes the development of tertiary lymphoid structures that support protective immunity but may perpetuate chronic inflammation during autoimmunity 5, 6 . Hence, the context of IL-17 signaling plays an important role in eliciting an inflammatory or tissue-protective response.
T H 17 cells are activated and differentiate in secondary lymphoid organs (SLOs) including the LNs and spleen, where they have an opportunity to interact with resident stromal cells during differentiation. Fibroblastic reticular cells are the critical non-hematopoietic stromal cells in SLOs. T cell zone FRCs were the first FRC population identified, characterized to express the chemokine CCL19 and IL-7 to attract T cells and support their survival 7 . They also secrete extracellular matrix (ECM) that ensheaths conduits carrying lymph for dendritic cell sampling, and forms a cellular scaffold that facilitates T cell migration 7 . In addition to T cell zone stroma, FRCs are now known to comprise heterogeneous subpopulations occupying distinct niches throughout the LN. Recent single cell-level analyses of LN stromal cells delineated seven podoplanin (PDPN) + FRC subpopulations 8 . These subsets include follicular dendritic cells (FDCs) in B cell follicles, marginal zone reticular cells (MRCs) in the subcapsullar sinus, two populations of medullary reticular cells known to support plasma cells 9 and three subsets of T zone reticular cells (TRCs): classical CCL19 hi TRCs, a CXCL9 + interfollicular TRC population and a CCL19 lo TRC population that expresses the survival factor B cell-activating factor (BAFF), and the B cell-attracting chemokine CXCL13 at B-T zone borders 10 . Depletion or dysfunction of FRCs in mouse models causes SLO follicular disorganization, reduced T and B cell viability and impaired antiviral immunity 10, 11 . The chronic fibrosis of LNs that occurs in infection by either human immunodeficiency virus or simian immunodeficiency virus exacerbates T cell loss due to reduced access to IL-7 from FRCs coated in excess ECM 12, 13 . Similar LN fibrosis with reduced FRC numbers was found in subjects from Uganda with chronic immune activation syndrome, corresponding to reduced T cell numbers and impaired antibody production following vaccination 14 . Conversely, FRCs regulate the magnitude of type 1 CD4 + T helper (T H 1) and CD8 + T cell responses through production of nitric oxide in response to interferon-γ [15] [16] [17] . Similarly, FRCs regulate type 1 innate lymphoid cell responses by reducing IL-15 production in response to MyD88 signaling 18 . Thus FRCs are thought to reduce immunopathology during viral infection. By presenting self-antigens, FRCs can delete self-reactive CD8 + T cells and induce CD4
+ regulatory T cells 19, 20 . Hence FRCs play important roles both in supporting and regulating adaptive immune responses.
Following pathogen invasion or immunization, activated dendritic cells migrate to local LNs and trigger endothelial 'shutdown' , generating a rapid increase in organ size due to retained
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Saikat Majumder 1 lymphocytes 21 . At first, cytoskeletal relaxation in the FRC allows stretching of the network 22 ; then, FRCs proliferate to provide the increased stromal support needed by the expanded lymphoid tissue 23, 24 . The kinetics of FRC proliferation are offset against increase in LN size by several days 24 , and more closely follow the activation kinetics of T cells, which are thought to provide proliferation-supporting signals 24, 25 . However, the nature of these signals remains unclear. In this study, we investigated the role of IL-17 produced by differentiating T H 17 cells on local FRCs during inflammation in SLOs.
Results
T H 17 cells drive increased ECM in inflamed LNs. Increased production of ECM components such as fibronectin and collagen is a feature of T H 17-mediated inflammation, including in the central nervous system in multiple sclerosis or its animal model experimental autoimmune encephalomyelitis (EAE) 26, 27 . Following immunization with the myelin oligodendrocyte glycoprotein peptide MOG (amino acids (aa) in complete Freund's adjuvant (CFA) to induce EAE, we observed that expression of Fn1 (encoding fibronectin) increased along with that of Il17a in draining LNs ( Supplementary Fig. 1a ). Immunization-induced Fn1 required IL-23R (Fig. 1a) , IL-17 was strongly induced only when OT-II cells expressed IL-23R (that is, WT OT-II) and did not require host IL-23R (Fig. 1b) . Similarly, Fn1 expression was increased only when OT-II cells were able to produce IL-17 (Fig. 1c) .
To determine whether IL-17 per se is required for increased Fn1 in inflamed LNs, we immunized Il17a -/-mice with MOG (aa 35-55) in CFA. Indeed, Fn1 expression was impaired in dLNs of Il17a -/-mice compared to WT following immunization (Fig. 1d) . Immunizationelicited Fn1 was dependent on IL-17RA and the signaling adapter Act1, further confirming the requirement for the IL-17 signaling pathway (Fig. 1e,f) . To confirm that these gene expression alterations resulted in protein changes, we performed immunofluorescence staining. Fibronectin expression again increased in WT but not in Il17ra -/-dLNs following immunization (Fig. 1g) . Expression of Col1a1, encoding collagen type 1a, was also increased in dLNs in an IL-17RA-dependent manner following immunization (Fig. 1h) but Col3a1 did not change, indicating an element of specificity in the ECM components that were regulated by IL-17 ( Supplementary  Fig. 1b) . Correspondingly, collagen deposition was increased in WT but not in Il17ra -/-mouse dLNs (Fig. 1i) . Despite these defects in ECM, the gross appearance, mass and cell numbers were similar between dLNs from immunized Il17ra
Il17
-/-and WT controls (Fig. 1j-l and Supplementary Fig. 1c ). These data thus suggested that T H 17 cells promote expression of ECM in inflamed dLNs through IL-17 signaling, independently of LN size or hypercellularity.
IL-17 signaling is required for FRC population expansion.
Fibroblastic reticular cells are the major cell type that expresses fibronectin and type I collagen in LNs 7 , and immunofluorescence staining confirmed co-localized expression of the FRC marker ER-TR7 with fibronectin in dLNs ( Supplementary Fig. 2a ). We therefore analyzed the stromal cell composition of naïve LNs and inflamed dLNs from immunized WT and Il17ra -/-mice. CD45 -CD31 -PDPN + FRCs were significantly increased in number in WT inflamed LNs and spleen from immunized animals, as compared to naïve, and this increase required IL-17 signaling because dLNs from immunized Il17ra
Il17
-/-mice had significantly lower FRC numbers, compared to those of WT (Fig. 2a,b and Supplementary Fig. 2b,c) . As further confirmation of the importance of IL-17 signaling in inflamed LNs, FRC numbers were reduced in the absence of Act1 (Fig. 2c) . Regnase-1 (encoded by Zc3h12a) is a potent negative regulator of IL-17 signaling 29 , and accordingly mice with reduced Regnase-1 expression had increased numbers of FRCs following immunization (Fig. 2d) (Fig. 2e,f and Supplementary Fig. 2b) . PDPN +
CD21
+ CD35 + FDCs and PDPN + MadCAM1 + MRCs were unchanged under IL-17 deficiency (Fig. 2g,h ). While not an exhaustive characterization of stromal cell subsets, these data suggested that the CD21 -
MadCAM1
-CCL19 + TRC population, which is also the largest and best positioned to interact with T H 17 cells, may be a functional target of IL-17 signaling in lymphoid tissues.
FRCs respond directly to IL-17 during inflammation. We next sought to determine the factors that regulate IL-17-dependent increases in FRC numbers. Lymphotoxin (LT)-α and LT-β are critical for the development, expansion and maintenance of FRC populations in LNs 11 . Lta and Ltb expression increased in response to immunization, but was not different between WT and Il17ra -/-mice, suggesting that IL-17 does not regulate lymphotoxin availability (Fig. 3a,b) . FRC numbers in LNs from naïve Il17ra -/-mice were similar to those from WT mice ( Supplementary Fig. 3a ), further supporting an IL-17-independent function of lymphotoxins in FRC development. To rule out any contribution of developmental defects to the impaired FRC response in Il17ra -/-mice, we immunized WT mice with MOG (aa in CFA and administered IL-17-neutralizing antibodies ( Supplementary Fig. 3b ). FRC numbers were again significantly lower in LNs from anti-IL-17-treated mice compared to isotype controls (Fig. 3c) , despite similar LN size between these groups ( Supplementary Fig. 3c ). Moreover, Fn1 expression was significantly reduced when IL-17 was neutralized ( Supplementary Fig. 3d ).
These data confirmed a role for IL-17 in promoting FRC proliferation in mature SLOs following immunization. However, they did not rule out an indirect effect of IL-17 within the LNs. For example, IL-17 signaling leads to neutrophil recruitment 30 and, accordingly, neutrophils were decreased in immunized Il17ra -/-dLNs compared to WT (Fig. 3d) . To determine whether IL-17 signaling is required in FRC, FRC ΔIl17ra mice were generated by crossing Il17ra fl/fl mice with the FRC-specific Ccl19
Cre (refs. 11,22,31 ; Supplementary Fig. 3e ). Ccl19
Cre ; Il17ra fl/+ littermates were analyzed as controls (FRC ctrl ). FRC ΔIl17ra showed no defect in neutrophil recruitment following immunization (Fig. 3e) , indicating that FRCs are not a necessary source of neutrophil-attracting chemokines in response to IL-17 signaling in LNs. As observed in Il17ra -/-dLNs, LEC and BEC numbers were unchanged in FRC ΔIl17ra ( Supplementary Fig. 3f,g ). Expression of Fn1 and Col1a1, but not Col3a1, was also significantly lower in FRC ΔIl17ra mice compared to FRC ctrl ( Supplementary  Fig. 3h-j) . Furthermore, numbers of FRCs in LNs of FRC ΔIl17ra mice were significantly decreased on days 12 and 15 post-immunization (Fig. 3f,g ). Thus we concluded that FRC-intrinsic IL-17 signaling is required for their successful proliferation during LN inflammation. (Fig. 4a,b) . The disruption of FRC stromal architecture in immunized FRC ΔIl17ra dLNs did not disrupt B and T cell zones, and frequencies of naïve and effector T cell populations, as well as IL-17-producing T H 17 cells, were unaffected ( Fig. 4c and Supplementary  Fig. 4a-c 
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-/- . j-l, Gross appearance (j), weight (k) and total cell counts (l). Data in k-l show mean ± s.d. pooled from two or three experiments. Each symbol represents an individual mouse, except that g, i and j are representative images from n = 4 mice per group. g and i were repeated twice, with similar results. P values calculated by one-way analysis of variance (ANOVA) except for f, k and l (by Student's t-test), *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. NS, not significant.
to then potentiate FRC proliferation, this is perhaps unsurprising in this acute model. However, there was a significant decrease in the frequency of germinal center B cells from immunized dLNs when FRCs could not respond to IL-17 ( Fig. 4d and Supplementary  Fig. 4c ), and a corresponding defect in induction of both total and MOG-specific IgG production (Fig. 4e,f) . BAFF is produced by FRCs to support B cell survival under homeostatic conditions 10 . IL-17 did not stimulate increased BAFF production in FRC in vitro (Fig. 4g) . However, corresponding to reduced numbers of FRC, BAFF levels were significantly decreased in LNs from immunized FRC ΔIl17ra mice (Fig. 4h) . Hence, the absence of IL-17 signaling in FRCs does not lead to global immune defects but does cause impaired B cell responses, most probably through reduced availability of BAFF at a critical juncture for germinal center formation and maintenance.
Colitis increases local IL-17-dependent FRC numbers. Complete
Freund's adjuvant is a potent, long-acting adjuvant, and we wanted to test whether the IL-17-dependent increase in FRC numbers was more broadly applicable to inflamed LNs. We therefore analyzed FRCs in gut-draining mesenteric LNs (MLNs) during dextran sulfate sodium (DSS)-induced colitis, a colon injury model in which IL-17 plays a protective role in restoring epithelial barrier integrity 3, 4 . As expected, Il17ra -/-mice developed more severe colitis, as determined by weight loss and colon length, while FRC ΔIl17ra mice developed colitis of similar severity to that of controls, since the gut epithelium response to IL-17 was intact (Fig. 5a-c and Supplementary Fig. 5a ). Naïve mice with FRC-specific ablation of IL-17RA showed no difference in MLN FRC numbers, as compared to those of littermate controls, again confirming that IL-17 is not required for FRC development ( Supplementary Fig. 5b ). Numbers of FRCs were higher in the inflamed MLNs of WT mice after administration of DSS, as compared to controls administered water only (Fig. 5d) . Strikingly, the colitis-driven MLN FRC population expansion was critically dependent on IL-17RA expression by FRC, rather than differing gut epithelial cell IL-17RA expression and disease severity in Il17ra -/-and FRC ΔIl17ra mice (Fig. 5d ). Therefore, these data support the conclusion that FRC-intrinsic IL-17RA expression is required for FRC remodeling in the dLN during inflammation that elicits an IL-17 response, regardless of the type of peripheral tissue insult.
IL-17 potentiates FRC proliferation and survival.
To further understand how IL-17 promotes FRC activation, we performed transcriptomic analysis of dLN FRCs isolated at day 12 postimmunization ( Supplementary Fig. 6a ). Known IL-17 targets were higher in WT compared to Il17ra -/-FRC ( Fig. 6a) , including genes encoding CXCL1, CXCL2, s100a8, s100a9, C/EBPβ and IκBζ 32 . Fitting with decreased FRC numbers, gene set enrichment analysis (GSEA) showed significant dysregulation of the cell cycle pathway in Il17ra -/-FRCs (Fig. 6b ). There was a trend towards reduced expression of the cell cycle-associated protein Ki67 in Il17ra -/-FRCs in LNs, and a significant decrease in Ki67 in spleen ( Fig. 6c and Supplementary Fig. 6b ,c). Ki67 marks all cells that have initiated the cell cycle. In fact, a number of the genes identified by GSEA as being increased in Il17ra -/-FRCs are negative regulators of the cell cycle, including Trp53, Nek2, Tfdp1, Chek2 and Rad17 (Fig. 6d) . We therefore analyzed cell cycle stages and found that similar proportions of cells were in gap 2/mitotic (G2/M) phase, but significantly fewer FRC ΔIl17ra cells were in synthesis phase, as compared to FRC ctrl , with an inverse trend towards increased G0/G1, which includes resting cells ( Fig. 6e and Supplementary  Fig. 6d ). Fibroblasts have been shown to actively express genes that maintain cellular quiescence and suppress proliferation following in vitro triggers of quiescence, such as growth factor withdrawal or cell contact inhibition 33 . Il17ra -/-FRCs showed high expression of these fibroblast quiescence-associated genes, as compared to c,d ,g,h, by Student's t-test), *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. were immunized for EAE and dLNs analyzed on day 15 (except f, day 12) by flow cytometry for neutrophils (e) and numbers of FRC (f,g). Data in c-g are pooled from two or three experiments, represented as mean ± s.d., and each symbol represents an individual mouse. P values calculated by one-way ANOVA (except c,e,f,g, by Student's t-test), *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. -d and g , by Student's t-test), *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
WT FRCs (Supplementary Fig. 6e ), further supporting that the cell cycle was stalled.
Cell cycle analysis also revealed increased numbers of apoptotic cells in IL-17RA-deficient FRCs (Fig. 6e) . There was no difference in total cell viability of digested WT and Il17ra -/-LNs, in accord with similar total LN cell numbers (Supplementary Fig. 6f ). However, GSEA pathway analysis supported significant upregulation of apoptotic pathways in IL-17RA-deficient FRCs (Fig. 6f) . Immunofluorescence staining confirmed significantly increased frequencies of cells that were positive for the apoptosis markers TUNEL and active caspase-3 in dLNs of immunized Il17ra -/-mice compared to WT (Fig. 6g,h and Supplementary Fig. 6g,h ). As further confirmation of the FRC-intrinsic role of IL-17 in maintaining FRC viability, there were significantly higher frequencies of apoptotic FRCs in dLNs from immunized FRC ΔIl17ra compared to controls ( Fig. 6i and Supplementary Fig. 6i ). Taken together, these data indicate a critical role for IL-17 in promoting the survival and continued proliferation of activated FRC.
IL-17 drives metabolic reprogramming in proliferating FRC.
Proliferation requires increased energy, and insufficient nutrient availability can be a cause of halted cell cycle and increased apoptosis in proliferating cells. Nutrient stress, including low glucose, leads to induction of autophagy through activation of adenosine monophosphate-activated protein kinase (AMPK) 34 . Il17ra -/-FRCs showed increased expression of genes regulating autophagy (Fig. 7a) , corresponding with increased activation of AMPK (Fig. 7b) . Glycogen synthase kinase (GSK)3-β phosphorylation can also be an indicator of glucose uptake and glycolysis 35 , and IL-17 signaling has previously been associated with regulation of GSK3-β activity 32 . Indeed, Il17ra -/-FRC showed decreased phosphorylation of GSK3-β (Fig. 7c) , further supporting a possible defect in energy metabolism in the absence of IL-17 signaling. We therefore directly assessed the ability of FRCs to take up glucose in vivo by injecting the fluorescent glucose analog 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose (2-NBDG) on day 12 postimmunization. FRCs from immunized LN had significantly higher 2-NBDG uptake compared to that of naïve controls (Fig. 7d,e and Supplementary Fig. 7a ), while FRCs from immunized Il17ra -/-, as well as FRC ΔIl17ra LN and spleen, showed a striking defect in 2-NBDG uptake (Fig. 7d-g and Supplementary Fig. 7b ). These data show that IL-17 signaling is required to increase the capacity for glucose uptake in proliferating FRCs.
To determine the functional metabolic capacity of FRCs activated in the presence or absence of IL-17, we performed Seahorse extracellular flux analysis on pooled LN and spleen FRCs from immunized WT and Il17ra -/-mice and compared these to those from naïve WT controls. Corresponding to increased glucose uptake, aerobic glycolysis (as assessed by ECAR) was increased following immunization in WT but not Il17ra -/-FRCs (Fig. 7h) . Similarly, WT FRCs from immunized mice showed a marked increase in basal OCR, indicating enhanced oxidative phosphorylation (Fig. 7i) , and correspondingly had a high spare respiratory capacity (SRC) compared to that of naïve FRCs (Fig. 7i,j) . In contrast, FRCs from immunized Il17ra -/-LN had relatively lower basal oxidative phosphorylation rates with minimal SRC, more similar to those of naïve FRCs (Fig. 7i,j) . Gene expression data supported the IL-17RA-dependent increases in metabolic activity: as compared to WT, FRCs from Il17ra -/-immunized LN had low gene expression of Hk2, encoding the inflammation-induced glycolytic enzyme HK2, and Cpt1a, encoding the rate-limiting enzyme of mitochondrial fatty acid oxidation, CPT1A, along with several subunits of mitochondrial complex I nicotinamide adenine dinucleotide plus hydrogen (NADH)-ubiquitinone oxidoreductase (Fig. 7k) . However, mitochondrial mass per FRC was not dependent on IL-17RA (not shown). We further confirmed that CPT1A protein expression was reduced when IL-17RA was specifically deleted in FRCs (Fig. 7l and Supplementary Fig. 7c) . These data thus demonstrate that IL-17 signaling is required for activated FRCs to increase their glucose uptake, glycolysis and, in particular, mitochondrial bioenergetic activity, corresponding with the requirement for IL-17 signaling in promoting successful proliferation of FRCs.
IL-17 promotes metabolic changes through IκBζ.
The data so far clearly implicate FRC-intrinsic IL-17 signaling in driving metabolic changes. However, FRCs isolated from naive LN and stimulated in vitro with IL-17 did not increase their glucose uptake, as assessed by 2-NBDG (Fig. 8a) . In contrast, dLN FRCs from mice immunized 6 d earlier showed increased 2-NBDG uptake in response to IL-17 stimulation (Fig. 8b) . These data therefore suggest that IL-17 modulation of glucose absorption requires that cells have first received 'priming' signals in an inflamed LN.
We then tested the converse question: does previous IL-17 signaling in vivo alter the threshold for glucose uptake in response to distinct stimuli? Lipopolysaccharide (LPS), a prototypical Toll-like receptor agonist known to drive glycolysis in myeloid cells, strongly increased glucose uptake in WT FRCs from immunized LN but not from naïve LN (Fig. 8c) . Interestingly, FRCs from immunized Il17ra -/-dLN did respond to LPS, but with significantly lower rates of glucose uptake than those of WT FRCs (Fig. 8c) , supporting the idea that FRCs receive activating signals that render them responsive to further stimuli but require IL-17 to reach full bioenergetic potential. One intriguing link between the IL-17 and LPS signaling pathways is that they both induce IκBζ, a co-activator of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signal transduction pathway, to drive a subset of target inflammatory genes 32, 36 . Nfkbiz, which encodes IκBζ, was accordingly lower in FRCs from immunized Il17ra -/-mice compared to WT controls (Fig. 6a) . IL-17 stimulation induced Nfkbiz expression in FRCs from day 6 primed LNs, as expected, and Nfkbiz expression was effectively depleted by siRNA (Fig. 8d) . IL-17-induced expression of Fn1 and Col1a1 was unaffected by Nfkbiz deletion, confirming that IL-17 signaling was intact and that IκBζ does not regulate all IL-17 target genes (Fig. 8e,f) . However, IL-17-stimulated glucose uptake was significantly decreased in Nfkbiz-deleted FRCs (Fig. 8g) . Furthermore, IL-17 induced Cpt1a expression in an Nfkbiz-dependent manner (Fig. 8h) . Therefore we conclude that IL-17 directs metabolic shifts in activated FRCs through induction of the transcriptional co-activator IκBζ, leading to increased glucose uptake and expression of rate-limiting enzymes for mitochondrial fatty acid oxidation and oxidative phosphorylation.
Discussion
The most well-known function of IL-17 is the promotion of inflammation through induction of chemokines and cytokines that recruit and activate myeloid cells during inflammation 32 . However, IL-17 is implicated in diseases that include proliferation of non-immune cells as a pathological feature, and it has been reported that IL-17 signaling promotes proliferation of keratinocytes in models of psoriasis 37 and skin tumorigenesis 38 , and of oligodendrocyte precursors in a model of multiple sclerosis 39 . Our finding that IL-17 potentiates proliferation and survival of FRCs through enhanced metabolic capacity now makes it very interesting to consider the potential contribution of IL-17-induced metabolic shifts in other cell targets, in the context of pathologic tissue remodeling and fibrosis that accompany chronic inflammation. In addition, our data lead us to speculate that metabolic changes could underlie the synergistic activity of IL-17 with lymphotoxin in driving de novo FRC differentiation and proliferation for tertiary lymphoid follicle formation in autoimmunity 6 . Interleukin-17 is known to play a critical role in promoting B cell antibody responses. IL-17-deficient mice have defective IgA and IgG1 responses to oral immunization with cholera toxin 40 . Similarly, IL-17 is required for the formation of germinal centers and antibody class-switching in models of autoimmune disease 41, 42 . The mechanisms by which IL-17 promotes B cell activation remain unclear. It has been proposed that T H 17 cells promote intestinal IgA production through conversion to T follicular helper cells that can then drive germinal center reactions 43 ; however, this does not explain the role of IL-17 itself. In immunized Il17ra -/-mice, T follicular helper cells are present in normal numbers but may not correctly localize to germinal center light zones 44 .
Complete depletion of FRCs in naïve Ccl19
Cre ; DTX fl/fl mice results in reduced numbers of T and B cells, disorganized B cell follicles and impaired adaptive immunity to influenza virus infection 10 . Although FRC numbers were reduced when they could not respond to IL-17, we did not find that Il17ra deficiency caused a clear defect in effector T cell responses in either EAE or DSS colitis. Similarly, total B cell and plasma cell frequencies were unchanged in EAE, suggesting that impaired antibody response in Il17ra -/-mice is not a simple outcome of reduced FRC numbers leading to reduced T and B cell survival. The connection between IL-17 signaling in FRCs and antibody response is particularly interesting in the context of autoimmune diseases, where both auto-antibody and T H 17 responses are commonly present.
Unlike lymphotoxin, IL-17 does not appear to be required for development of the FRC network. Instead, the role of IL-17 in promoting metabolic fitness was restricted to inflammation-induced FRC proliferation. The corresponding finding that FRC from naïve mice were unresponsive to IL-17-stimulated glucose uptake leads us to speculate that IL-17 acts as 'signal 2' in FRC activation, while previous signals such as clec2, mechanical stretch or lymphotoxin provide 'signal 1' to drive proliferation. Given the roles of FRCs in SLO homeostasis, it seems probable that this provides an extra layer of regulation to avoid tolerance breakdown due to inappropriate activation of FRCs. It is thus interesting to speculate that IL-17-stimulated FRCs are more prone to inappropriate or exaggerated responses to activating stimuli due to their heightened metabolic status, providing a clue to the involvement of IL-17 in loss of tolerance and in relapses that characterize autoimmune inflammation.
IL-17 is itself a relatively weak activator of NF-κB signaling 45 , but it strongly synergizes with other NF-kB-activating cytokines, including tumor necrosis factor and lymphotoxin 32 . IL-17 signaling will inevitably synergize with additional cytokines present in the inflamed local milieu, making the profound impact of IL-17 deficiency even more remarkable under T H 17-activating conditions. The observation that IL-17 signaling lowered the threshold of activated FRCs to stimulation from LPS suggested that the heightened metabolic function of IL-17-stimulated stromal cells is an additional modus operandi for the synergistic activities of IL-17 with a surprising range of cytokines and Toll-like receptor stimuli. IL-17 signaling not only directly modulates gene expression through NF-κB activation but also strongly alters signaling transduction networks through induction of transcriptional regulators 32 . IκBζ is an inducible transcriptional co-activator with NF-κB in driving inflammatory cytokine expression, in response to stimulation of either the IL-17-Act1 (ref. 45 ) or Toll-like receptor/IL-1-Myd88 pathways 36 . IκBζ expression is negatively regulated by Regnase-1 (ref. 29 ), corresponding to increased FRC numbers in mice with reduced Regnase-1 activity. Although IκBζ has not previously been linked to metabolism, it has been shown to promote
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-/- survival of epithelial cells 46 and B cell lymphoma cells 47 , the latter through co-activation of NF-κB. Indeed, NF-κB activity links metabolism to cell survival in cancer cells by increasing mitochondrial respiration 48, 49 and glucose uptake 50 . It will be interesting in future to further investigate the molecular mechanisms by which IκBζ regulates metabolism, and the associated influence on inflammation. Since IκBζ did not regulate ECM production, this also suggests that divergent IL-17 signaling pathways could be targeted in disease states to separate tissue remodeling and fibrosis effects from cell metabolism and proliferation. -/-EAE dLNs (day 12) were cultured in media or in the presence of LPS, and glucose uptake was measured via luciferase assay to detect 2-deoxyglucose-6-phosphate. Data are pooled from two experiments, represented as mean ± s.d., and each symbol represents an individual mouse. d-f, FRCs were transfected in triplicate with IκBζ small interfering RNA (siRNA) for 24 h, then stimulated with IL-17 for 12 h before analysis. d, Nfkbiz gene expression. e, Fn1 gene expression. f, Collagen 1a (Col1a1) gene expression. g, Glucose-uptake competency assessed by flow cytometry of 2-NBDG added for final 30 min of culture. h, Cpt1a gene expression. All gene expression was normalized to that of Gapdh. Data in d-h are representative of two independent experiments, represented as mean ± s.d., and each symbol represents an individual mouse. P values calculated by one-way ANOVA, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
In conclusion we show that, during T H 17 cell differentiation in dLNs, IL-17 signals to FRCs had a profound impact on LN stromal organization by promoting FRC activation through a phenotypic switch from quiescence to a highly metabolically active phenotype. Most strikingly, IL-17 deficiency resulted in stalled proliferation and increased apoptosis of FRCs, accompanied by signs of severe metabolic stress. Hence these data reveal the intimate connections between differentiation of a pro-inflammatory effector T H 17 response and alterations in the FRC network that support the inflamed hypercellular LN environment, with outcomes on B cell adaptive responses. These findings provide insight into the mechanisms by which T H 17 cells can mediate inflammation and tissue remodeling in lymphoid organs, and support further investigation of this role for IL-17 in peripheral tissue targets of T H 17-dependent inflammation.
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